Skip to main content
NY-ESO-1 T-Cell Immunotherapy for Recurrent or Refractory Ovarian Cancer: Clinical Effectiveness
( Last Updated : November 15, 2018)
Project Sub Line:
- What is the clinical effectiveness of NY-ESO T-cell immunotherapy in adults with recurrent or refractory ovarian cancer?